Lipocine Net Income Per Share from 2010 to 2026

LPCN Stock  USD 8.72  0.09  1.02%   
Lipocine Net Income Per Share yearly trend continues to be very stable with very little volatility. Net Income Per Share is likely to grow to 0 this year. During the period from 2010 to 2026, Lipocine Net Income Per Share quarterly data regression pattern had range of 41.65 and standard deviation of  10.65. View All Fundamentals
 
Net Income Per Share  
First Reported
2010-12-31
Previous Quarter
0.001408
Current Value
0.001478
Quarterly Volatility
10.65306125
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Lipocine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipocine's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.8 M or Total Revenue of 13.5 M, as well as many indicators such as Price To Sales Ratio of 2.54, Dividend Yield of 0.0 or PTB Ratio of 1.17. Lipocine financial statements analysis is a perfect complement when working with Lipocine Valuation or Volatility modules.
  
Build AI portfolio with Lipocine Stock
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
Evaluating Lipocine's Net Income Per Share across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Lipocine's fundamental strength.

Latest Lipocine's Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Lipocine over the last few years. It is Lipocine's Net Income Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lipocine's overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Lipocine Net Income Per Share Regression Statistics

Arithmetic Mean(7.49)
Coefficient Of Variation(142.28)
Mean Deviation8.42
Median(3.10)
Standard Deviation10.65
Sample Variance113.49
Range41.65
R-Value0.29
Mean Square Error110.67
R-Squared0.09
Significance0.25
Slope0.62
Total Sum of Squares1,816

Lipocine Net Income Per Share History

2026 0.001478
2025 0.001408
2024 0.001564
2023 -3.1
2022 -2.15
2021 -0.19
2020 -6.46

About Lipocine Financial Statements

Lipocine investors utilize fundamental indicators, such as Net Income Per Share, to predict how Lipocine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year

Pair Trading with Lipocine

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipocine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lipocine Stock

  0.71JNJ Johnson JohnsonPairCorr

Moving against Lipocine Stock

  0.9HPQ HP IncPairCorr
  0.61BRK-A Berkshire HathawayPairCorr
  0.61MSFT MicrosoftPairCorr
  0.5VLCN Volcon Inc Symbol ChangePairCorr
  0.38IBM International BusinessPairCorr
The ability to find closely correlated positions to Lipocine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipocine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipocine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipocine to buy it.
The correlation of Lipocine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipocine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipocine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipocine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Pharmaceuticals sector continue expanding? Could Lipocine diversify its offerings? Factors like these will boost the valuation of Lipocine. Expected growth trajectory for Lipocine significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipocine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.02)
Revenue Per Share
0.806
Quarterly Revenue Growth
5.954
Return On Assets
(0.21)
Return On Equity
(0.33)
Understanding Lipocine requires distinguishing between market price and book value, where the latter reflects Lipocine's accounting equity. The concept of intrinsic value - what Lipocine's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lipocine's price substantially above or below its fundamental value.
Understanding that Lipocine's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipocine represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lipocine's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.